CRISPR/Cas9 May Aid Cancer Immunotherapy by Identifying Checkpoint Escapes

06:43 EDT 20 Jul 2017 | Genetic Engineering News

Checkpoint inhibitors, drugs designed to “release the brakes” on cancer-fighting immune cells, have shown promise in treating cancer patients, albeit a minority of cancer patients. To help checkpoint inhibitors help the immune system fight cancer, scientists are investigating combination treatments , such as pairings of the most potent checkpoint inhibitors and new drugs that could effectively shut down molecular pathways that serve as programmed cell death protein 1 (PD-1) escape mechanisms. The trick, however, is to identify these molecular pathways. A new means of doing so has been demonstrated by scientists based at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. These scientists report that they have used CRISPR/Cas9 genome-editing technology to test the function of thousands of tumor genes in mice. Essentially, the scientists systematically screened for drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors. The scientists, led by pediatric oncologist W. Nick ...

Original Article: CRISPR/Cas9 May Aid Cancer Immunotherapy by Identifying Checkpoint Escapes


More From BioPortfolio on "CRISPR/Cas9 May Aid Cancer Immunotherapy by Identifying Checkpoint Escapes"

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...